After promising M&A and buybacks to revive long-term prospects, Biogen refreshes board with three appointments to enthuse investors
Bruised by the titanic failure of its Alzheimer’s drug aducanumab and ahead of gene therapy competition for its flagship SMA treatment Spinraza, Biogen is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
